|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.06.25 - 12:02
|
Gefürchteter Hedgefonds nistet sich bei BB Biotech und HBM ein (Cash)
|
|
|
Beteiligungsnahmen - Ein Hedgefonds steigt zeitnah erst bei BB Biotech und nun auch bei HBM ein. Die Amerikaner sind bekannt für ihre aktive Einflussnahme bei Unternehmen. Bauen sie ihre Aktienpakete aus oder läuft es bloss auf ein kurzes Gastspiel hinaus?...
|
|
|
24.06.25 - 13:33
|
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson′s Disease (Business Wire)
|
|
|
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson's disease; topline data anticipated in 2027SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor, with significant support from existing investors Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman) Ltd., and Acorn Bioventures. The Company also announced the first patient has been dosed in the global Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson's disease (PD).
“The Series D financing represents further endorsement of Neuron23's industry-leading approach, w...
|
|
|
|
|
|
|
|
|
22.05.25 - 14:03
|
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib (Business Wire)
|
|
|
Financing extends Company's cash runway beyond important clinical milestones anticipated beginning in 2H25, supporting the ongoing execution of the FORTE Master Protocol evaluating plixorafenib as a monotherapy in three distinct patient populations
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare dedicated investors participated, including SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, and 3B Future Health Fund. This $38 million adds to the $75 million raised as part of the earlier Series D and D-1 financings, for an aggregate total to date of $113 million for this Series D financing.
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance t...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
